DS‐3032b (milademetan tosylate hydrate; hereafter called milademetan) inhibits the interaction between MDM2 and p53 and has shown tumor growth inhibition and induction of apoptosis in both in vitro and in vivo cancer models with wild‐type p53.19 Here, TP53 is linked to cancer.